Bristol Myers Squibb (BMY) balance sheet and financial health

Pharmaceuticals · NYSE · Health Care

$61.35 -2.51% Close Nov 17, 2026 Live

TrendArc score 46 of 100 · Health 6.7 · Momentum 5.1 · Moat 4.4 · scored Nov 17, 2026 · How the score works

Cash and short-term investments less borrowings, September 30, 2026

$30.3 billion more borrowings than cash

Bristol Myers Squibb held $12.6 billion of cash and short-term investments against $42.9 billion of borrowings on September 30, 2026. Its lease liabilities, shown apart from borrowings, were $1.9 billion.

Borrowings to equity

1.83

$42.9B of borrowings on $23.4B of equity, Sep 2026

Return on invested capital

13.3%

latest quarter to September 2026, annualised; the stock card's measure

Cash and borrowings at each fiscal year end

$20.0B$40.0B$60.0B2016201720182019202020212022202320242025Cash and short-terminvestments $10.7BBorrowings $45.1B$20.0B$40.0B$60.0B20172019202120232025Cash and short-term investments $10.7BBorrowings $45.1B

What the balance sheet holdsSeptember 30, 2026

Assets $88.8BSmaller items: long-term investments $378MCash and short-term investments$12.6BReceivables$10.6BInventory$2.70BOther current assets$3.84BProperty, goodwill and other$58.6BFunded by $88.8BBorrowings$42.9BLease liabilities$1.93BOther liabilities$20.6BShareholders' equity$23.4BAssets $88.8BCash and short-term investments$12.6BReceivables$10.6BInventory$2.70BOther current assets$3.84BLong-term investments$378MProperty, goodwill and other$58.6BFunded by $88.8BBorrowings$42.9BLease liabilities$1.93BOther liabilities$20.6BShareholders' equity$23.4B

"Other liabilities" is total liabilities less borrowings and lease liabilities; "Property, goodwill and other" is total assets less the current assets and long-term investments.

Balance sheet, the last 10 fiscal year ends

In billions of US dollars, at each fiscal year end, named by the month it ended; the first column is the newest balance sheet on file. Borrowings are bonds, notes, loans and commercial paper; lease liabilities, operating and finance, are shown apart.
Fiscal year endLatest
Sep 2026
Dec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
Assets
Cash and short-term investments12.610.710.912.39.317.015.815.48.86.86.3
Receivables10.611.410.710.99.99.48.57.75.76.35.5
Inventory2.72.72.62.72.32.12.14.31.21.21.2
Other current assets3.84.65.65.95.84.83.82.02.00.60.6
Total current assets29.829.429.831.827.333.330.229.417.714.913.7
Long-term investments0.40.40.30.40.00.00.40.81.82.52.7
Total assets88.890.092.695.296.8109.3118.5129.935.033.633.7
Liabilities and equity
Current liabilities18.823.423.822.321.921.919.118.310.79.68.8
Borrowings42.945.149.639.839.344.650.746.77.38.06.7
Lease liabilities1.92.01.61.71.41.0—0.8———
Total liabilities65.471.576.265.765.773.380.678.220.921.717.4
Minority interests and other0.00.00.00.00.00.00.00.00.00.00.2
Shareholders' equity23.418.516.329.431.135.937.851.614.011.716.2
Financial health
Cash less borrowings-30.3-34.4-38.8-27.5-30.1-27.6-34.8-31.31.4-1.1-0.4
Borrowings to equity1.832.443.041.351.271.241.340.910.520.680.41

Interest cover is operating income over interest expense, for full fiscal years. Minority interests and other is total assets less total liabilities and shareholders' equity (calculated by TrendArc). Company filings as standardised by Tiingo; borrowings and lease liabilities told apart with the lines the company files on SEC EDGAR, and a dash where the two cannot be told apart. Rebuilt nightly.

Bristol Myers Squibb against its peers

CompanyCash less borrowingsBorrowings to equityInterest coverReturn on invested capital
Corcept TherapeuticsCORT +$371M 0.00 — 59.2%
ZoetisZTS -$7.52B 2.74 16.1x 20.1%
ViatrisVTRS -$11.5B 0.97 — -5.2%
Johnson & JohnsonJNJ -$27.4B 0.55 26.0x 0.7%
Bristol Myers SquibbBMY -$30.3B 1.83 — 13.3%
MerckMRK -$44.1B 1.20 15.6x 21.4%
Eli LillyLLY -$44.6B 1.23 — 29.6%
PfizerPFE -$48.4B 0.70 — 8.7%

Each company's newest balance sheet; borrowings leave lease liabilities out; interest cover for its newest fiscal year; return on invested capital is the stock card's measure. A dash where a measure does not apply.

Next

Follow Bristol Myers Squibb with a free account.

A watchlist, price alerts and saved chart layouts. No card needed.

Sign up free

No forecast, no recommendation. This page describes Bristol Myers Squibb from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.

The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.